Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

Jianbiao Zhou; Chonglei Bi; Shaw-Cheng Liu; Wee-Joo Chng; Kian-Ghee Tay; Hanry Yu; Keith Glaser; Daniel Albert; Steven K Davidsen; Chien-Shing Chen

Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

Jianbiao Zhou
, Chonglei Bi
, Shaw-Cheng Liu
, Wee-Joo Chng
, Kian-Ghee Tay
, Hanry Yu
, Keith Glaser
, Daniel Albert
, Steven K Davidsen
, Chien-Shing Chen

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	112
State	Published - Nov 16 2008

Disciplines

Biology
Oncology
Immunology and Infectious Disease

OpenUrl availability

Full text

Cite this

@article{4835768cb8084b628453a71ee0f2697a,

title = "Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.",

author = "Jianbiao Zhou and Chonglei Bi and Shaw-Cheng Liu and Wee-Joo Chng and Kian-Ghee Tay and Hanry Yu and Keith Glaser and Daniel Albert and Davidsen, \{Steven K\} and Chien-Shing Chen",

note = "Abstract. Internal tandem duplication of fms-like tyrosine kinase 3 (FLT3-ITD) mutation occurs in about 25\% of acute myeloid leukemia (AML) patients and is ass",

year = "2008",

month = nov,

day = "16",

language = "American English",

volume = "112",

journal = "Blood",

}

TY - JOUR

T1 - Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

AU - Zhou, Jianbiao

AU - Bi, Chonglei

AU - Liu, Shaw-Cheng

AU - Chng, Wee-Joo

AU - Tay, Kian-Ghee

AU - Yu, Hanry

AU - Glaser, Keith

AU - Albert, Daniel

AU - Davidsen, Steven K

AU - Chen, Chien-Shing

N1 - Abstract. Internal tandem duplication of fms-like tyrosine kinase 3 (FLT3-ITD) mutation occurs in about 25% of acute myeloid leukemia (AML) patients and is ass

PY - 2008/11/16

Y1 - 2008/11/16

UR - http://www.bloodjournal.org/content/112/11/1618.abstract

M3 - Article

VL - 112

JO - Blood

JF - Blood

ER -

Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

Disciplines

OpenUrl availability

Other files and links

Cite this